Wang Yiping, Pan Tao, Wang Qiong, Guo Zhen
Department of Digestive Disease, Huaxi Hospital of Sichuan University, Guoxuexiang 37#, Chengdu, Sichuan Province, China, 610041.
Cochrane Database Syst Rev. 2009 Oct 7(4):CD004275. doi: 10.1002/14651858.CD004275.pub3.
Nocturnal gastric acid breakthrough (NAB) is defined as intragastric pH<4 for more than one continuous hour overnight. Adding H(2)-receptor antagonists (H2RAs) at bedtime to high-dose proton pump inhibitors is likely to enhance nocturnal gastric pH control and decrease nocturnal gastric acid breakthrough.
To assess the effectiveness of additional bedtime H2-receptor antagonists in suppressing nocturnal gastric acid breakthrough and the incidence of adverse effects.
We identified eligible trials by searching The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 4, 2008), MEDLINE (1966-August 2008), EMBASE (1980-August 2008) and CINAHL (1982-August 2008). We re-ran the search on CENTRAL (The Cochrane Library Issue 4, 2008), and in MEDLINE, EMBASE and CINAHL in June 2004, July 2005, August 2006 and August 2008.
All randomized controlled trials evaluating H2-receptor antagonists for the control of nocturnal gastric acid breakthrough were eligible for inclusion.
Two reviewers have independently selected the trials to be included in the review according to the pre-stated eligibility criteria. Disagreements were resolved by a third reviewer. If the data could not be pooled for meta-analysis, a narrative description was provided.
8 small randomized controlled trials were included for meta-analysis. The results show that additional bedtime H2RAs can decrease the prevalence rate of nocturnal gastric acid breakthrough. The results of the analyses for secondary outcomes show that additional bedtime H2RAs can decrease the percentage of time during which pH is less than 4.0 inside the stomach and promote median intragastric pH.
AUTHORS' CONCLUSIONS: We can conclude no implications for practice at this stage. Appropriately designed large-scale randomized controlled trials with long-term follow-up are needed to determine the effects of additional bedtime H2RAs in suppressing nocturnal gastric acid breakthrough.
夜间胃酸突破(NAB)定义为夜间胃内pH值连续1小时以上低于4。睡前加用H2受体拮抗剂(H2RAs)至大剂量质子泵抑制剂可能会增强夜间胃pH值的控制并减少夜间胃酸突破。
评估睡前加用H2受体拮抗剂抑制夜间胃酸突破的有效性及不良反应发生率。
通过检索Cochrane对照试验中央注册库(CENTRAL)(2008年第4期Cochrane图书馆)、MEDLINE(1966年至2008年8月)、EMBASE(1980年至2008年8月)和CINAHL(1982年至2008年8月)来确定符合条件的试验。我们于2004年6月、2005年7月、2006年8月和2008年8月在CENTRAL(2008年第4期Cochrane图书馆)以及MEDLINE、EMBASE和CINAHL中重新进行了检索。
所有评估H2受体拮抗剂控制夜间胃酸突破的随机对照试验均符合纳入标准。
两名评价员根据预先设定的纳入标准独立选择纳入综述的试验。分歧由第三位评价员解决。如果数据无法合并进行荟萃分析,则提供叙述性描述。
纳入8项小型随机对照试验进行荟萃分析。结果表明,睡前加用H2RAs可降低夜间胃酸突破的发生率。次要结局的分析结果表明,睡前加用H2RAs可降低胃内pH值低于4.0的时间百分比,并提高胃内pH值中位数。
我们可以得出结论,现阶段对实践没有影响。需要进行适当设计的长期随访大规模随机对照试验,以确定睡前加用H2RAs抑制夜间胃酸突破的效果。